Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEE011 with Fulvestrant and PI3K Inhibitors in Advanced Breast Cancer
NCT02088684Phase 1Completed
- Sponsor
- Novartis
- Start
- May 2014
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 1, open-label trial of ribociclib in breast cancer (3 arms), sponsored by Novartis. Primary endpoints: Incidence of Dose Limiting Toxicities at 28 days and Progression Free Survival at 36 months. Started May 2014; status: completed.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02088684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02088684.